Advertisement





Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 49:2350-2355, doi:10.1016/j.jacc.2007.02.054 (Published online 1 June 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2007.02.054v1
49/24/2350    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conen, D.
Right arrow Articles by Osswald, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Conen, D.
Right arrow Articles by Osswald, S.

CLINICAL RESEARCH: HEART RHYTHM DISORDER

Amiodarone-Induced Thyrotoxicosis

Clinical Course and Predictors of Outcome

David Conen, MD*, Ludovic Melly*, Christoph Kaufmann, MD*, Stefan Bilz, MD{dagger}, Peter Ammann, MD*, Beat Schaer, MD*, Christian Sticherling, MD*, Beat Muller, MD{dagger} and Stefan Osswald, MD, FACC, FESC*,*

* Department of Cardiology, University Hospital, Basel, Switzerland
{dagger} Department of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital, Basel, Switzerland.

Manuscript received August 23, 2006; revised manuscript received February 8, 2007, accepted February 12, 2007.

* Reprint requests and correspondence: Dr. Stefan Osswald, Cardiology, University Hospital, Petersgraben 4, 4031 Basel, Switzerland. (Email: sosswald{at}uhbs.ch).

Objectives: This study sought to determine the clinical course and predictors of long-term outcome in patients with documented amiodarone-induced thyrotoxicosis (AIT).

Background: Amiodarone-induced thyrotoxicosis is a condition that is difficult to manage, in particular because of the long half-life of amiodarone. Data on optimal treatment for AIT are scarce.

Methods: We performed a retrospective review among patients with documented AIT at a tertiary care center. Baseline characteristics, treatment received, laboratory parameters, and events during follow-up were evaluated. The predefined composite end point consisted of the following AIT-associated complications: death, heart transplantation, hospitalization for heart failure, myocardial infarction, stroke, hospitalization for arrhythmia management, or hospitalization for treatment complications.

Results: Eighty-four patients were included in the present analysis; 27 patients received prednisone for AIT. There was no difference in time to normalization of free thyroxine between those receiving and those not receiving prednisone. Long-term follow-up showed high morbidity and mortality; 47 patients (56%) reached the primary end point. Patients receiving prednisone had a worse outcome than those not receiving prednisone (p = 0.003). Although patients received prednisone for 84 ± 65 days, curves started to separate only 12 months after the initial diagnosis.

Conclusions: Patients with AIT have a high event rate during follow-up. Prednisone had no effect on time to normalization of thyroxine levels and was associated with an increased event rate. Importantly, AIT-related problems must be expected late, at a time when thyroid function is under control.

Abbreviations and Acronyms
  AIT = amiodarone-induced thyrotoxicosis
  fT4 = free thyroxine
  IQR = interquartile range
  T3 = triiodothyronine
  TSH = thyroid-stimulating hormone




This article has been cited by other articles:


Home page
Eur Heart JHome page
J. P. Piccini, J. S. Berger, and C. M. O'Connor
Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials
Eur. Heart J., May 2, 2009; 30(10): 1245 - 1253.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K.-H. Yiu, M.-H. Jim, C.-W. Siu, C.-H. Lee, M. Yuen, M. Mok, Y.-F. Shea, K. Fan, H.-F. Tse, and W.-H. Chow
Amiodarone-Induced Thyrotoxicosis Is a Predictor of Adverse Cardiovascular Outcome
J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 109 - 114.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement